SD-1029
Based on 1 publication(s) in Google Scholar
SD-1029 is a JAK2/STAT3 inhibitor. SD-1029 inhibits STAT3 nuclear translocation. SD-1029 is an inhibitor of STAT3 activation due to inhibition of JAK2 phosphorylation.
For research use only. We do not sell to patients.
- Purity : 88.8%
- CAS No.: 118372-34-2
- Formula: C25H32Br2Cl2N2O3
- Molecular Weight:639.25
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications Citing Use of MedChemExpress (MCE) SD-1029
More
Biological Activity
Description
IC50 & Target
[1]|
STAT3 |
JAK2 |
In Vitro
SD-1029 (10 μM) inhibits EGFP-Stat3 nuclear translocation in BHK-21 and U-2OS cells[1].
SD-1029 (5 and 10 μM; 24 hours) inhibits cell growth and induces apoptosis in OVCAR8TR ovarian cancer cells[1].
SD-1029 (10 μM; 24 hours) suppresses p-Stat3 levels in human breast and ovarian cancer cell lines[1].
SD-1029 inhibits not only JAK2 phosphorylation, but also the phosphorylation of STAT1 and STAT3. SD-1029 strongly inhibits Tyk2 phosphorylation, implicating both JAK2 and Tyk2 as upstream requirements for IL-23-induced IL-23R expression[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:OVCAR8TR ovarian cancer cells
-
Concentration:5 and 10 μM
-
Incubation Time:24 hours
-
Result:Down-regulated cell proliferation, and induced apoptotic cell death.
Treatment resulted in a marked, 20-fold induction of apoptosis in the OVCAR8TR cells that express constitutively activated Stat3.
-
Cell Line:MDA-MB-468 and MDA435 (breast cancer), OV1063 (ovarian cancer), and the paclitaxel-resistant ovarian cancer daughter lines, SKOV-3TR and OVCAR8TR.
-
Concentration:10 μM
-
Incubation Time:24 hours
-
Result:Led to reduced levels of pStat3.
Chemical Information
-
CAS No. 118372-34-2
-
Appearance Solid
-
Molecular Weight 639.25
-
Formula C25H32Br2Cl2N2O3
-
Color White to off-white
-
SMILES
O=C1C(C(C2=CC=C(Cl)C(Cl)=C2)C3=C(CCC(CN(C)C)C3=O)O4)=C4CCC1CN(C)C.[H]Br.[H]Br
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Exp Ther Med
CX3CL1/CX3CR1 axis alleviates inflammation and apoptosis in human nucleus pulpous cells via M2 macrophage polarization. [Abstract]2023 Jun 7;26(1):359. PMID: 37324510
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Cytoplasmic-Nuclear Fractionated Protein Extraction
Cytoplasmic-nuclear fractionated protein extraction separates soluble cytoplasmic proteins from nuclear-enriched proteins by mild plasma-membrane permeabilization, differential centrifugation, washing of nuclei, and extraction of nuclear proteins for downstream immunoblotting or related molecular analysis. The readout is the relative abundance of a protein in cytoplasmic and nuclear fractions, commonly assessed by western blotting together with compartment markers such as tubulin or pyruvate kinase for cytoplasm and lamin, nucleoporin, hnRNP, H2AX, or Lamin B for nuclear fractions.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Zhenfeng Duan, et al. SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation. Clin Cancer Res. 2006 Nov 15;12(22):6844-52. [Content Brief]
[2]. Nor Fazila Che Mat, et al. Interleukin-23-induced interleukin-23 receptor subunit expression is mediated by the Janus kinase/signal transducer and activation of transcription pathway in human CD4 T cells. J Interferon Cytokine Res. 2011 Apr;31(4):363-71. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)